10180762Developing the health economic and budget impact model case for the aflo® inhaler optimisation platform in moderate - severe asthmaActiveCollaborative R&DInnovate UK**Over 400M live with asthma globally - 30M in Europe and 26M in the US**. **UK asthma mortality is the worst in Europe**. Globally, **annual costs exceed $363B**, **driven by 'uncontrolled asthma'**. In the **UK there are 5.4M asthmatics with a total cost to the economy of over £22B/ year**. **Only 1.8% of public research spend** goes toward lung conditions. Although inhaled medicines work well when taken correctly, many patients do not receive the full benefit. Up to **90% of people make errors when using an inhaler**, and many do not take their medication as prescribed. This results in poor drug delivery to the lungs, uncontrolled symptoms, Emergency Department visits, hospital admissions and, in many cases, **preventable deaths**. The main causes are **poor adherence**, **incorrect inhaler technique**, and **environmental triggers**. These factors make up to **40--50% of total spend**. Global guidelines (NICE, GINA and GOLD) emphasise the importance of checking and correcting inhaler technique. Studies suggest that **30--50% of patients escalated to expensive biologic medicines may not need them** if poor adherence or technique is addressed first - representing nearly **$2 billion** in potential global savings. The **UK-patented aflo platform** was developed to fix this problem. Supported by four Innovate UK awards, Asthma + Lung UK and private investment, aflo provides **automated inhaler-technique training**, **timely prompts**, **environmental trigger insights** and **advanced data analytics**. In a 2024 UK randomised controlled trial, aflo produced significant improvements in asthma control, quality of life and inhaler proficiency and **over 90% user satisfaction with** potential **cost savings exceeding 40%**. **NHS resource allocation requires robust clinical and cost effectiveness evidence**. Demonstrating the cost-effectiveness of aflo in key asthma cohorts is crucial to both NHS and international adoption and scaling. **This project will develop clinical and cost effectiveness models across the asthma severity spectrum, initially for the UK, with adjustable assumptions for global application. Evidence shows that inhaler optimisation cost impact models are sparse and of poor quality. Developing a robust, adaptable Business Impact Model for the aflo platform is a disruptive approach** **with the potential to unlock health-system savings estimated in the tens of millions per year through avoided asthma exacerbations and more efficient use of high-cost medicines**, based on early economic estimates. The initial focus is the UK, with adaptable assumptions for the US and Europe. Early pilot data in the Netherlands and the US, combined with favourable reimbursement pathways, strengthen global market potential.